(12) Patent Application Publication (10) Pub. No.: US 2004/0170574 A1 Bleckmann Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2004/0170574 A1 Bleckmann Et Al US 2004O170574A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0170574 A1 Bleckmann et al. (43) Pub. Date: Sep. 2, 2004 (54) AUTOMATICALLY FOAMING OR (57) ABSTRACT FOAM-TYPE PREPARATIONS COMPRISING Self-foaming and/or foam-like cosmetic or dermatological NORGANIC GEL FORMERS preparations which comprise I. an emulsifier System which consists of (76) Inventors: Andreas Bleckmann, Ahrensburg (DE); A. at least one emulsifier Achosen from the group of Rainer Kropke, Schenefeld (DE); wholly neutralized, partially neutralized or unneu Heidi Riedel, Hamburg (DE) tralized branched and/or unbranched, Saturated and/or unsaturated fatty acids having a chain Correspondence Address: length of from 10 to 40 carbon atoms, GREENBLUM & BERNSTEIN, P.L.C. B. at least one emulsifier B chosen from the group of 1950 ROLAND CLARKE PLACE polyethoxylated fatty acid esters having a chain RESTON, VA 20191 (US) length of from 10 to 40 carbon atoms and a degree of ethoxylation of from 5 to 100 and (21) Appl. No.: 10/469,695 C. at least one coemulsifier C chosen from the group of Saturated and/or unsaturated, branched and/or unbranched fatty alcohols having a chain length of (22) PCT Filed: Mar. 14, 2002 from 10 to 40 carbon atoms, II. up to 30% by weight-based on the total weight of (86) PCT No.: PCT/EPO2/O2851 the preparation-of a lipid phase, III. 1 to 90% by volume, based on the total volume of (30) Foreign Application Priority Data the preparation, of at least one gas chosen from the group consisting of air, OXygen, nitrogen, helium, Mar. 15, 2001 (DE)..................................... 101 13 047.3 argon, nitrous oxide (N2O) and carbon dioxide Publication Classification (CO) IV. 0.01-10% % by weight of one or more gelling (51) Int. Cl." ............................... A61K 9/00; A61K 7/00 agents chosen from the group of the inorganic thick (52) U.S. Cl. ................................................................ 424/47 CCS. US 2004/0170574 A1 Sep. 2, 2004 AUTOMATICALLY FOAMING OR FOAM-TYPE pellant liquid mixture escapes through a fine nozzle, and the PREPARATIONS COMPRISING INORGANIC GEL propellant evaporates, leaving behind a foam. FORMERS 0009. After-foaming cosmetic preparations are also 0001. The present invention relates to self-foaming and/ known per Se. They are firstly applied to the skin from an or foam-like cosmetic and dermatological preparations, in aeroSol container in flowable form and, after a short delay, particular to skincare cosmetic and dermatological prepara develop the actual foam only once they are on the skin under tions. the effect of the after-foaming agent present, for example a Shaving foam. After-foaming preparations are often in Spe 0002 Foams or foam-like preparations are a type of cific formulation forms, Such as, for example, after-foaming disperse System. Shaving gels or the like. 0003. By far the most important and best known disperse 0010. However, the prior art does not include any sort of Systems are emulsions. Emulsions are two- or multi-phase cosmetic or dermatological preparations which could be Systems of two or more liquids which are insoluble or only foamed as early as during the preparation and nevertheless slightly Soluble in one another. The liquids (pure or as have a Sufficiently high Stability in order to be packaged in Solutions) are present in an emulsion in a more or less fine the usual manner, Stored and put onto the market. distribution, which generally has only limited stability. 0011. An object of the present invention was therefore to 0004 Foams are structures of gas-filled, spherical or enrich the prior art and to provide cosmetic or dermatologi polyhedral cells which are delimited by liquid, Semiliquid, cal Self-foaming and/or foam-like preparations which do not high-viscosity or solid cell ribs. The cell ribs, connected via have the disadvantages of the prior art. points of interSection form a continuous framework. The 0012 German laid-open specification DE 197 54 659 foam lamellae stretch between the cell ribs (closed-cell discloses that carbon dioxide is a Suitable active ingredient foam). If the foam lamellae are disturbed or if they flow back for Stabilizing or increasing the epidermal ceramide Synthe into the cell rib at the end of foam formation, an open-cell sis rate, which may serve to enhance the permeability foam is obtained. Foams are also thermo-dynamically barrier, reduce the transepidermal water loSS and increase unstable Since a reduction in the Surface area leads to the the relative skin moisture. To treat the skin, the CO is, for production of Surface energy. The Stability and thus the example, dissolved in water, which is then used to rinse the existence of a foam is thus dependent on to what extent it is skin. However, the prior art hitherto does not include any possible to prevent its Self-destruction. Sort of cosmetic or dermatological bases in which a gaseous 0005 Cosmetic foams are usually dispersed systems of active ingredient could be incorporated in an adequate, i.e. liquids and gases, where the liquid represents the dispersant effective, concentration. and the gas represents the dispersed Substance. Foams of 0013. It was thus a further object of the present invention low-viscosity liquids are temporarily Stabilized by Surface to find cosmetic or dermatological bases into which effective active Substances (Surfactants, foam stabilizers). Because of amounts of gaseous active ingredients can be incorporated. their large internal Surface area, Such Surfactant foams have a high adsorption capacity, which is utilized, for example, in 0014. It was surprising and could not have been foreseen cleaning and washing operations. Accordingly, cosmetic by the perSon Skilled in the art that Self-foaming and/or foams are used, in particular, in the fields of cleansing, for foam-like cosmetic or dermatological preparations which example as Shaving foam, and of haircare. comprise 0006 To generate foam, gas is bubbled into suitable 0015 I. an emulsifier System which consists of liquids, or foam formation is achieved by Vigorously beat 0016 A. at least one emulsifier Achosen from the ing, Shaking, Spraying or Stirring the liquid in the gas group of wholly neutralized, partially neutralized atmosphere in question, provided that the liquids comprise or unneutralized branched and/or unbranched, Suitable Surfactants or other interface-active Substances Saturated and/or unsaturated fatty acids having a (“foam formers”), which, apart from interfacial activity, also chain length of from 10 to 40 carbon atoms, have a certain film-forming ability. 0017 B. at least one emulsifier B chosen from the 0007 Cosmetic foams have the advantage over other group of polyethoxylated fatty acid esters having cosmetic preparations of permitting a fine distribution of a chain length of from 10 to 40 carbon atoms and active ingredients on the Skin. However, cosmetic foams can a degree of ethoxylation of from 5 to 100 and generally only be achieved using particular Surfactants, 0.018 C. at least one coemulsifier C chosen from which, moreover, are often not well tolerated by the skin. the group of Saturated and/or unsaturated, 0008 A further disadvantage of the prior art is that such branched and/or unbranched fatty alcohols having foams have only low stability, for which reason they usually a chain length of from 10 to 40 carbon atoms, collapse within approximately 24 hours. A requirement of 0019 II. up to 30% by weight-based on the total cosmetic preparations, however, is that they have Stability weight of the preparation-of a lipid phase, for years, as far as possible. This problem is generally taken into account by the fact that the consumer produces the 0020 III. 1 to 90% by volume, based on the total actual foam himself just before use using a Suitable Spray Volume of the preparation, of at least one gas chosen System for which purpose, for example, it is possible to use from the group consisting of air, OXygen, nitrogen, Spray cans in which a liquefied preSSurized gas Serves as helium, argon, nitrous oxide (N2O) and carbon diox propellant gas. Upon opening the pressure valve, the pro ide (CO) US 2004/0170574 A1 Sep. 2, 2004 0021) IV. 0.01-10% % by weight of one or more 0028. The invention further provides for gelling agents chosen from the group of the inor 0029 the use of self-foaming and/or foam-like cos ganic thickeners, metic or dermatological preparations which com 0022 overcome the disadvantages of the prior art. prise 0030) I. an emulsifier System which consists of 0023. According to the prior art to date, foam-like cos metic emulsions which are characterized by a high intro 0.031 A. at least one emulsifier Achosen from the duction of air cannot be formulated or prepared industrially group of wholly neutralized, partially neutralized without propellent gas. This is true in particular for Systems or unneutralized branched and/or unbranched, which are based on classic emulsifiers and gelling agents Saturated and/or unsaturated fatty acids having a and develop a foam with an extraordinarily high Stability as chain length of from 10 to 40 carbon atoms, a result of shearing (stirring, homogenization). As a result of 0.032 B. at least one emulsifier B chosen from the the invention, the introduction of the gases is aided, and a group of polyethoxylated fatty acid esters having Stabilizing and Significantly after-foaming effect is achieved a chain length of from 10 to 40 carbon atoms and over a prolonged Storage period, even at relatively high a degree of ethoxylation of from 5 to 100 and temperatures (e.g. 40 C.), without comprising after-foam 0.033 C. at least one coemulsifier C chosen from ing agents customary according to the prior art, Such as, for the group of Saturated and/or unsaturated, example, by propellent gases.
Recommended publications
  • Determination of the Major Flavonoid from Qina (Eucalyptus Globules L.) Using Shift Reagent, UV and IR Spectrophotometry
    Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam B.Sc. Science and Education, El-Zeim Alazhari University( 2003) Postgraduate Diploma in Applied Chemistry, Gezira University( 2009) A Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science in Chemistry Department of Applied Chemistry and Chemical Technology Faculty of Engineering and Technology Supervisor: Prof.Mohamed Abdel Karim Mohamed Co-supervisor:Dr. Mohamed Osman Babiker October -2012 ~1~ Determination Of The Major Flavonoid From Qina (Eucalyptus globules L.) Using Shift Reagent, UV And IR Spectrophotometry. BY Leni Ali Edris Adam Examination Committee: Name Position Signature Prof.Mohamed Abdel Karim Mohame Chairperson ................. Dr. Abo Bakr Khidir Ziada Intarnal Examiner …………. Dr. Abd Elsalam Abdalla Dafa Alla Extarnal Examiner …….. Date OF Examination: 6\10\2012 ~2~ Dedication This work is dedicated to My father who Deserved all respect, my mother For her care and passion, my husband for his help and support, my family and Friends. ~3~ Acknowledgements I thank Allah, Almighty for help. I wish to express my deep gratitude to my supervisor Prof. Mohamed Abdel Karim Mohamed for supervision and advice. I am grateful to all those who helped me to finish this thesis. My thanks are also extended to my colleagues for kind support. ~4~ Abstract Qina bark (Eucalyptus globules.L) is used in ethnomedicine as anti- inflammatory and antimalarial remedy.This study was aimed to extract and determine the physiochemical properties of the major flavonoid of quina bark. The plant material was collected from northern Kordofan and extracted with ethanol.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • EP1776161B1.Pdf
    (19) TZZ____T (11) EP 1 776 161 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61Q 5/02 (2006.01) A61Q 7/00 (2006.01) 26.10.2016 Bulletin 2016/43 A61Q 19/00 (2006.01) A61K 8/36 (2006.01) A61K 8/362 (2006.01) A61K 8/37 (2006.01) (2006.01) (2006.01) (21) Application number: 05718804.7 A61K 8/39 A61Q 1/02 A61Q 5/06 (2006.01) A61K 8/64 (2006.01) A61Q 5/12 (2006.01) A61Q 11/00 (2006.01) (22) Date of filing: 25.04.2005 A61K 8/81 (2006.01) A61Q 19/06 (2006.01) A61Q 19/08 (2006.01) A61K 8/97 (2006.01) A61K 8/42 (2006.01) A61K 8/49 (2006.01) A61Q 5/00 (2006.01) A61K 8/73 (2006.01) (86) International application number: PCT/IB2005/051344 (87) International publication number: WO 2005/102266 (03.11.2005 Gazette 2005/44) (54) COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE UDP GLUCURONOSYL TRANSFERASE (UGT) ENZYMES INDUCER KOSMETISCHE ODER DERMOPHARMAZEUTISCHE ZUSAMMENSETZUNG MIT MINDESTENS EINEM UDP-GLUCURONOSYL-TRANSFERASE (UGT) ENZYM-INDUKTOR COMPOSITION COSMETIQUE OU DERMOPHARMACEUTIQUE COMPRENANT AU MOINS UN INDUCTEUR D’ENZYMES UDP-GLUCURONOSYLTRANSFERASES (UGT) (84) Designated Contracting States: • PATENT ABSTRACTS OF JAPAN vol. 2000, no. DE ES FR GB IT 14, 5 March 2001 (2001-03-05) & JP 2000 319154 A(NIPPON MENAADEKESHOHIN KK; ICHIMARU (30) Priority: 26.04.2004 FR 0404408 PHARCOS CO LTD), 21 November 2000 (2000-11-21) (43) Date of publication of application: • DATABASE WPI Derwent Publications Ltd., 25.04.2007 Bulletin 2007/17 London, GB; AN 2001-481491 XP002309671 CHEOUNG J H ET AL.: "Chrysin 7-o-crotonate, its (73) Proprietor: Sederma S.A.S.
    [Show full text]
  • 1 Revealing SARS-Cov-2 Functional Druggability Through Multi-Target
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 11 May 2020 doi:10.20944/preprints202005.0199.v1 Revealing SARS-CoV-2 Functional Druggability Through Multi-Target Cadd Screening of Repurposable Drugs Yash Gupta1,2, Dawid Maciorowski1,3, Raman Mathur1, Catherine M Pearce1, David J. IIc1,3, Hamza Husein1,3, Ajay Bharti4, Daniel P. Becker3, Brijesh Rathi2,5, Steven B Bradfute6, Ravi Durvasula1,2, Prakasha Kempaiah1,2* 1 Loyola University Chicago Stritch School of Medicine, Chicago, IL, 60153, USA; 2 Department of Medicine, Loyola University Medical Center, Chicago, IL, 60153, USA; 3 Loyola University Chicago, Chicago, IL, USA; 4 Division of Infectious Diseases, Department of Medicine, University of California, San Diego, CA, 92093, USA, 5 Laboratory for Translational Chemistry and Drug Discovery, Hansraj College, University of Delhi, India; 6 Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA. Number of Tables: 10; Number of Figures: 16 ABSTRACT: The emergence of SARS/MERS drug resistant COVID-19 with high transmission and mortality has recently been declared a deadly pandemic causing economic chaos and significant health problems. Like all coronaviruses, SARS-CoV-2 is a large virus that has many druggable components within its proteome. In this study, we focused on repurposing approved and investigational drugs by identifying potential drugs that are predicted to effectively inhibit critical enzymes within SARS-CoV-2. We shortlisted seven target proteins with enzymatic activities known to be essential at different stages of the virus life cycle. For virtual screening, the energy minimization of a crystal structure or modeled protein was carried out using Protein Preparation Wizard (Schrödinger LLC, 2020-1).
    [Show full text]
  • Flavonoid Compounds Benzquercin (R!NN)
    Gilenya; Norw. : Gilenya; Spain: Gilenya; Swed.: Gilenya; reintroduction of fingolimod if treatment has been stopped Oxerutins (BAN) for more than 2 weeks, and the precautions for re�initiating Switz.: Gilenya; Turk.: Gilenya; UK: Gilenya; USA: Gilenya. treatment outlined above should be followed. Hidroxileti!rut6sidos; Hydroxyethyir�tosides; Oxerutlnas: Fingolimod may increase the risk of developing 0Kcepynmot infections due to the reduction in peripheral lymphocyte Flavonoid Compounds Description. Oxerutins consist of a mixture of 5 different count (see Uses and Administration, p. 2504.3), and 0-(P-hydroxyethyl)rutosides, not less than 45% of which is mo f!avonoides; 8iofiavonoids; Flavonoides: Vitarnin treatment should not be started in patients without a recent P troxerutin (trihydroxyethylrutoside, below), but which also Substances; Vitamlnas full blood count taken within the previous 6 months. P; <DnqBOHOMj:jol. includes monohydroxyethylrutoside, dihydroxyethylruto­ Fingolimod should not be started in patients with active side, and tetrahydroxyethylrutoside. acute or chronic infections. Patients should be monitored Benzquercin (r!NN) for signs and symptoms of infection during treatment and Quercetin for 2 months after treatment has stopped. Stopping Benzqueccina; Benzquercine; Benzquercinum; 6et!3KB€PLi�H. fingolimod should be considered if a patient develops a 3,3',4';5,7-Pentakis(benzyloxy) flavone. Quercetina; Keep:.;erv.H: 3,3',4',5,7-Pentahydroxyftavone. serious infection during treatment, and then the risks versus C,oKNJ0,=752.9 2-(3,4-Dihydroxyphenyl)-3,5,7-trihy droxy�4H- 1 -benzopyran- benefits reassessed before treatment is resumed. 4--one, Patients without a history of chickenpox or who have not C4$ - 13157-90-9. received varicella Mzoster vaccination should be tested for UN/! - 499L710 905.
    [Show full text]
  • Daflon® 500 Mg Tablets
    Vasoprotectives Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases Final Report LBI-HTAProject Report No./Projektbericht Nr.: 79 ISSN: 1992-0488 ISSN-online: 1992-0496 Vasoprotectives Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases Final Report Vienna, December 2014 Project Team/Projektteam Project Management/Projektleitung: Dr. rer. soc.oec. Ingrid Zechmeister-Koss Authors/AutorInnen: Dipl. Ges-oec. Stefan Fischer Dr. rer. soc.oec. Ingrid Zechmeister-Koss Additional contribution/Projektbeteiligung: Dr. Anna Glechner (Danube University Krems, performedmeta-analysis) Systematic Literature Search/Systematische Literatursuche: Tarquin Mittermayr, BA Hand Search/Handsuche: Stefan Fischer External Review/Externe Begutachtung: Priv.-Doz. Dr. med. univ. Thomas Gary (Klinische Abteilung für Angiologie, Meduni Graz) Dipl.-Ing. Erich Kvas (Hermesoft, Graz) Internal Review/Interne Begutachtung: Priv.-Doz. Dr. phil. Claudia Wild Correspondence/Korrespondenz: Stefan Fischer: [email protected] This report should be referenced as follows/Dieser Bericht soll folgendermaßen zitiert werden: Fischer S, Zechmeister-Koss I: Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoidal diseases. LBI-HTA Project Report No.: 79, 2014, Vienna: Ludwig Boltzmann Institute for Health Technology Assessment. Conflict of Interest/Interessenskonflikt All authors declare no conflict of interest in sense
    [Show full text]
  • Ep 2858641 B1
    (19) TZZ __T (11) EP 2 858 641 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/352 (2006.01) A61K 31/35 (2006.01) 06.09.2017 Bulletin 2017/36 A61P 17/00 (2006.01) A61Q 1/06 (2006.01) A61Q 1/14 (2006.01) A61K 8/49 (2006.01) (2006.01) (2006.01) (21) Application number: 13800034.4 A61K 8/60 A61Q 17/04 A61Q 19/08 (2006.01) A61K 8/86 (2006.01) A61Q 19/10 (2006.01) A61K 8/97 (2017.01) (22) Date of filing: 06.06.2013 A61K 8/99 (2017.01) A61Q 19/00 (2006.01) (86) International application number: PCT/US2013/044464 (87) International publication number: WO 2013/184884 (12.12.2013 Gazette 2013/50) (54) IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION VERBESSERTES VERFAHREN FÜR PFLANZEN- UND/ODER ALGENEXTRAKTION PROCÉDÉS AMÉLIORÉS POUR L’EXTRACTION DE VÉGÉTAUX ET/OU D’ALGUES (84) Designated Contracting States: • JUDD, Christopher AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Riverhead, NY 11901 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • RICHTER, Nicole Jeannine PL PT RO RS SE SI SK SM TR Port Jefferson, NY 11777 (US) (30) Priority: 06.06.2012 US 201261656221 P (74) Representative: Herzog, Fiesser & Partner Patentanwälte PartG mbB (43) Date of publication of application: Isartorplatz 1 15.04.2015 Bulletin 2015/16 80331 München (DE) (73) Proprietors: (56) References cited: • BASF Corporation WO-A1-2011/140655 KR-B1- 100 741 644 Florham Park, NJ 07932 (US) US-A1- 2006 078 633 US-A1- 2006 099 690 • BASF Beauty Care Solutions France SAS US-A1- 2011 190 175 69007 Lyon (FR) • MINUTH, T.
    [Show full text]
  • Supplementary Materials: Comprehensive
    Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S1 of S14 Supplementary Materials: Comprehensive Ingredients Qualitative Profiling of Chinese Herbal Formula Wu-Zhu-Yu Decoction Based on Mass Defect and Fragment Filtering Approach Using High Resolution Mass Spectrometry Huarong Xu, Huibin Niu, Bosai He, Chang Cui, Qing Li and Kaishun Bi Figure S1. Fragmentation pattern of goshuyuamide and hydroxygoshuyuamide. (A) Representative fragments of goshuyuamide and hydroxygoshuyuamide; (B) product ion MS/MS spectrum of goshuyuamide; (C) product ion MS/MS spectrum of hydroxygoshuyuamide. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S2 of S14 Figure S2. (A) Fragmentation pathways and product ion MS/MS spectrums of (A) PPD type ginsenoside Rd and (B) PPT type ginsenoside Re. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S3 of S14 Figure S3. Fragmentation pathways and product ion MS/MS spectrums of rutin in (A) positive and (B) negative ion mode. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S4 of S14 Figure S4. Fragmentation pathways and product ion MS/MS spectrums of chlorogenic acid in (A) positive and (B) negative ion mode. Molecules 2016, 21, 664; doi:10.3390/molecules21050664 S5 of S14 Table S1. Characterization of the ingredients in Wu-Zhu-Yu decoction by LC high resolution MS. Ion Theoretical Measured Error/ No. Compound Formula tR/min Product Ions (m/z, Da) Adduction m/z (Da) m/z (Da) ppm Evodiamine and its analogous alkaloids 134.0599, 161.0711, 176.0707, 148.0394, 146.0597, 120.0446, 160.0636, 1 Dihydroxyevodiamine
    [Show full text]
  • Target and Suspect Screening of Contaminants of Emerging Concern in Raw Water and Drinking Water from Europe and Asia
    Water Research 198 (2021) 117099 Contents lists available at ScienceDirect Water Research journal homepage: www.elsevier.com/locate/watres What’s in the water? –Target and suspect screening of contaminants of emerging concern in raw water and drinking water from Europe and Asia ∗ Rikard Tröger a, , Hanwei Ren b, Daqiang Yin b, Cristina Postigo c, Phuoc Dan Nguyen d, Christine Baduel e, Oksana Golovko a,f, Frederic Been g, Hanna Joerss h, Maria Rosa Boleda i, Stefano Polesello j, Marco Roncoroni k, Sachi Taniyasu l, Frank Menger a, Lutz Ahrens a, Foon Yin Lai a, Karin Wiberg a a Department of Aquatic Sciences and Assessment, Swedish University of Agricultural Sciences (SLU), Box 7050, SE-750 07 Uppsala, Sweden b Key Laboratory of Yangtze River Water Environment, Ministry of Education, College of Environmental Science and Engineering, Tongji University, Shanghai 20 0 092, China c Water, Environmental, and Food Chemistry Unit (ENFOCHEM), Department of Environmental Chemistry, Institute of Environmental Assessment and Water Research (IDAEA-CSIC), Carrer Jordi Girona 18-26, Barcelona, 08034, Spain d Centre Asiatique de Recherche sur l’Eau, Ho Chi Minh City University of Technology, 268 Ly Thuong Kiet, District 10; Vietnam National University of Ho Chi Minh City, Linh Trung Ward, Thu Duc District, Ho Chi Minh City, Vietnam e Université Grenoble Alpes, IRD, CNRS, Grenoble INP, IGE, 38 050 Grenoble, France f University of South Bohemia in Ceske Budejovice, Faculty of Fisheries and Protection of Waters, South Bohemian Research Center of Aquaculture
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]